The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ...

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

In a European study, higher consumption of fruits, vegetables, legumes, and potatoes was associated with a reduced risk of ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term ...

A new study led by Johns Hopkins researchers has identified a significant gap between the number of U.S. patients for whom cholesterol-lowering drugs ...